Literature DB >> 11313789

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease.

Y Taniyama1, R Morishita, M Aoki, H Nakagami, K Yamamoto, K Yamazaki, K Matsumoto, T Nakamura, Y Kaneda, T Ogihara.   

Abstract

Hepatocyte growth factor (HGF) exclusively stimulates the growth of endothelial cells without replication of vascular smooth muscle cells, and acts as a survival factor against endothelial cell death. Recently, a novel therapeutic strategy for ischemic diseases using angiogenic growth factors to expedite and/or augment collateral artery development has been proposed. We have previously reported that intra-arterial administration of recombinant HGF induced angiogenesis in a rabbit hindlimb ischemia model. In this study, we examined the feasibility of gene therapy using HGF to treat peripheral arterial disease rather than recombinant therapy, due to its disadvantages. Initially, we examined the transfection of 'naked' human HGF plasmid into a rat hindlimb ischemia model. Intramuscular injection of human HGF plasmid resulted in a significant increase in blood flow as assessed by laser Doppler imaging, accompanied by the detection of human HGF protein. A significant increase in capillary density was found in rats transfected with human HGF as compared with control vector, in a dose-dependent manner (P < 0.01). Importantly, at 5 weeks after transfection, the degree of angiogenesis induced by transfection of HGF plasmid was significantly greater than that caused by a single injection of recombinant HGF. As an approach to human gene therapy, we also employed a rabbit hindlimb ischemia model as a preclinical study. Naked HGF plasmid was intramuscularly injected in the ischemic hindlimb of rabbits, to evaluate its angiogenic activity. Intramuscular injection of HGF plasmid once on day 10 after surgery produced significant augmentation of collateral vessel development on day 30 in the ischemia model, as assessed by angiography (P < 0.01). Serial angiograms revealed progressive linear extension of collateral arteries from the origin stem artery to the distal point of the reconstituted parent vessel in HGF-transfected animals. In addition, a significant increase in blood flow was assessed by a Doppler flow wire and the ratio in blood pressure of the ischemic limb to the normal limb was observed in rabbits transfected with HGF plasmid as compared with rabbits transfected with control vector (P < 0.01). Overall, intramuscular injection of naked human HGF plasmid induced therapeutic angiogenesis in rat and rabbit ischemic hindlimb models, as potential therapy for peripheral arterial disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313789     DOI: 10.1038/sj.gt.3301379

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  37 in total

1.  Tissue-specific characteristics of in vivo electric gene: transfer by tissue and intravenous injection of plasmid DNA.

Authors:  Oranuch Thanaketpaisarn; Makiya Nishikawa; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Pharm Res       Date:  2005-06-08       Impact factor: 4.200

2.  Dual delivery of vascular endothelial growth factor and hepatocyte growth factor coacervate displays strong angiogenic effects.

Authors:  Hassan K Awada; Noah R Johnson; Yadong Wang
Journal:  Macromol Biosci       Date:  2014-01-23       Impact factor: 4.979

Review 3.  Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology.

Authors:  Andrea Caporali; Magnus Bäck; Mat J Daemen; Imo E Hoefer; Elizabeth A Jones; Esther Lutgens; Christian M Matter; Marie-Luce Bochaton-Piallat; Arndt F Siekmann; Judith C Sluimer; Sabine Steffens; José Tuñón; Cecile Vindis; Jolanda J Wentzel; Seppo Ylä-Herttuala; Paul C Evans
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

4.  Myocardial regenerative therapy using a scaffold-free skeletal-muscle-derived cell sheet in patients with dilated cardiomyopathy even under a left ventricular assist device: a safety and feasibility study.

Authors:  Yasushi Yoshikawa; Shigeru Miyagawa; Koichi Toda; Atsuhiro Saito; Yasushi Sakata; Yoshiki Sawa
Journal:  Surg Today       Date:  2017-08-18       Impact factor: 2.549

5.  Assessment of myocardial blood perfusion improved by CD151 in a pig myocardial infarction model.

Authors:  Hou-juan Zuo; Zheng-xiang Liu; Xiao-chun Liu; Jun Yang; Tao Liu; Sha Wen; Dao-wen Wang; Xin Zhang
Journal:  Acta Pharmacol Sin       Date:  2008-12-15       Impact factor: 6.150

6.  Percutaneous nonviral delivery of hepatocyte growth factor in an osteotomy gap promotes bone repair in rabbits: a preliminary study.

Authors:  Hidenori Matsubara; Hiroyuki Tsuchiya; Koji Watanabe; Akihiko Takeuchi; Katsuro Tomita
Journal:  Clin Orthop Relat Res       Date:  2008-09-24       Impact factor: 4.176

7.  Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres.

Authors:  Toshihiro Kushibiki; Kunio Matsumoto; Toshikazu Nakamura; Yasuhiko Tabata
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

8.  Utility of Hepatocyte Growth Factor as a Biomarker for Early Diagnosis of Pulmonary Artery Hypertension.

Authors:  Mingting Liang; Ying Pang; Shuguang Zhang; Mei Zhang
Journal:  Mol Diagn Ther       Date:  2016-10       Impact factor: 4.074

9.  The partitioning of nanoparticles to endothelium or interstitium during ultrasound-microbubble-targeted delivery depends on peak-negative pressure.

Authors:  Y-H Hsiang; J Song; R J Price
Journal:  J Nanopart Res       Date:  2015-08-22       Impact factor: 2.253

10.  Mechanisms of Amplified Arteriogenesis in Collateral Artery Segments Exposed to Reversed Flow Direction.

Authors:  Joshua L Heuslein; Joshua K Meisner; Xuanyue Li; Ji Song; Helena Vincentelli; Ryan J Leiphart; Elizabeth G Ames; Brett R Blackman; Brett R Blackman; Richard J Price
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-03       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.